GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » EPS (Diluted)

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) EPS (Diluted) : $0.68 (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co EPS (Diluted)?

Chugai Pharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $0.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.68.

Chugai Pharmaceutical Co's EPS (Basic) for the three months ended in Mar. 2024 was $0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.68.

Chugai Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2024 was $0.15. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $0.68.

During the past 12 months, Chugai Pharmaceutical Co's average EPS without NRIGrowth Rate was 3.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 14.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 26.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 25.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Chugai Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 47.70% per year. The lowest was -17.40% per year. And the median was 12.35% per year.


Chugai Pharmaceutical Co EPS (Diluted) Historical Data

The historical data trend for Chugai Pharmaceutical Co's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co EPS (Diluted) Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.63 0.81 0.84 0.69

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.18 0.16 0.19 0.15

Competitive Comparison of Chugai Pharmaceutical Co's EPS (Diluted)

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's PE Ratio falls into.



Chugai Pharmaceutical Co EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Chugai Pharmaceutical Co's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(2260.513-0)/3290.920
=0.69

Chugai Pharmaceutical Co's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(496.607-0)/3291.172
=0.15

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chugai Pharmaceutical Co  (OTCPK:CHGCY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Chugai Pharmaceutical Co EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines